Nude foxn1nu mice

Manufactured by Inotiv

Sourced in France, Italy, Israel

Nude-Foxn1nu mice are a strain of immunodeficient mice characterized by the lack of a functional thymus gland, resulting in the absence of mature T cells. These mice are commonly used in research to study immune system function and as host models for tumor xenografts.

Automatically generated - may contain errors

Lab products found in correlation

Living image software, by PerkinElmer (3 mentions) Matrigel, by Corning (3 mentions) Matrigel, by BD (2 mentions) Sevoflurane, by Baxter (1 mentions) Ivis lumina 2, by PerkinElmer (1 mentions) Ivis lumina luminometer, by PerkinElmer (1 mentions) D luciferin, by Promega (1 mentions) Amicon centrifugal filter unit, by Merck Group (1 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (1 mentions) Mda mb 231 breast cancer cells, by American Type Culture Collection (1 mentions) Rneasy kit, by Qiagen (1 mentions) Corn oil, by Merck Group (1 mentions) Matrigel, by Thermo Fisher Scientific (1 mentions) Contour next, by Ascensia Diabetes Care (1 mentions) Physiosuite, by Kent Scientific (1 mentions) Td 110839, by Inotiv (1 mentions) Growth factor reduced matrigel, by Corning (1 mentions) Ivis spectrum in vivo imaging system, by PerkinElmer (1 mentions)

Close spelling variants of this product

Male athymic nude-Foxn1nu mice Female nude (Hsd:Athymic Nude-Foxn1nu) mice Athymic Nude-Foxn1nu/Foxn1+ mice Nude-foxn1nu female mice Immunodeficient athymic nude-FoxN1nu/nu mice Foxn1nu (Swiss nude) mice Hsd:Athymic Nude-Foxn1nu female mice NU-Foxn1nu nude mice Athymic nude-Foxn1nu female mice Hsd:Athymic Nude-Foxn1nu mice

26 protocols using nude foxn1nu mice

Xenograft-Driven Peritoneal Tumor Model

Check if the same lab product or an alternative is used in the 5 most similar protocols

Eight weeks old, female athymic, nude-foxn1nu mice (21 g average body weight, ENVIGO, NM horst, the Netherlands) were monitored for general health during one week before the start of the study. After conditioning, 12 mice underwent a midline laparotomy under general anesthesia with Sevoflurane (Baxter, Deerfield, USA) after which they were bilaterally injected via the subperitoneal route with 5.0 × 10⁵ SKOV3- Luc-IP1 cells suspended in 50 μl of Matrigel® (Life Sciences, Antwerp, Belgium) to facilitate the growth of peritoneal tumor nodules (Figure 1(a)). All mice were given subcutaneous pain relief (Ketoprofen, 150 µl) immediately after the procedure. Their weight and general wellbeing were monitored during recovery.
To assess the success rate of tumor induction and monitor tumor growth, a bioluminescence scan (IVIS Lumina II, Perkin Elmer) was acquired 14 days post-injection (Figure 1(b)). Each animal was injected intraperitoneally with Luciferine (D-Luciferin, PerkinElmer, Waltham, USA) using a dose of 150 mg/kg body weight. During the first scan, a calibration series was performed to assess the time after injection at which the signal was maximal. For subsequent scans, the same waiting period was maintained.

Steuperaert M., Debbaut C., Carlier C., De Wever O., Descamps B., Vanhove C., Ceelen W, & Segers P. (2019). A 3D CFD model of the interstitial fluid pressure and drug distribution in heterogeneous tumor nodules during intraperitoneal chemotherapy. Drug Delivery, 26(1), 404-415.

+ Open protocol

+ Expand

Subcutaneous Tumor Induction in Athymic Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Female athymic Nude-Foxn1nu mice (18 to 28 g, 7 weeks, Envigo, Horst, The Netherlands) were group-housed in pre-sterilized cages under standard conditions (20–24 °C, 40–70% relative humidity, 12-h light/dark cycles) and provided with ad libitum access to sterilized water and irradiated sterilized Teklad mouse food. Animal experiments were performed in accordance with the European Community Council Directive (2010/63/EU) for laboratory animal care and the Dutch Law on animal experimentation. The experimental protocol was validated and approved by the central committee for animal experimentation (CCD) and the local committee on animal experimentation of the VU University Medical Center. Animals were allowed to acclimate for at least one week before the injection of tumor cells. Subcutaneous tumors were induced by injecting a suspension of 2.2–2.5 × 10⁶ A549 or H1975 cells in PBS, in both flanks under isoflurane anesthetics (1–2% in oxygen). Once most tumors reached a suitable size (100 to 200 mm³), the mice were used for the studies (3–5 weeks p.i.) for A549, 2–3 weeks for H1975).

Högnäsbacka A.A., Poot A.J., Plisson C., Bergare J., Bonsall D.R., McCluskey S.P., Wells L.A., Kooijman E., Schuit R.C., Verlaan M., Beaino W., van Dongen G.A., Vugts D.J., Elmore C.S., Passchier J, & Windhorst A.D. (2024). Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor. EJNMMI Research, 14, 19.

+ Open protocol

+ Expand

Xenograft Tumor Growth Delay Study

Check if the same lab product or an alternative is used in the 5 most similar protocols

Five to six week old female Hsd:athymic Nude-Foxn1^nu mice (Envigo) were used for growth delay studies. Mice were kept in the Association for Assessment and Accreditation of Laboratory Animal Care-approved Wisconsin Institute for Medical Research Animal Care Facility. Animals were housed in specific pathogen-free rooms, and their clinical health was evaluated weekly. Studies involving the mice were carried out in accordance with an animal protocol approved by the University of Wisconsin.
NCI-H1581 and NCI-H226 tumor cells were mixed 1:1 with Matrigel (BD Biosciences) and injected subcutaneously into bilateral flanks of nude mice at 1 × 10⁶ cells/site. Tumor volume was measured twice weekly with Vernier calipers and calculated according to the relationship

V = (\frac{π}{6}) x (large diameter) x (small diameter)^{2}

. Once average tumor size reached 200 mm^{3 (link)}, mice were randomized into treatment groups (8–10 mice).

SenthilKumar G., Fisher M.M., Skiba J.H., Miller M.C., Brennan S.R., Kaushik S., Bradley S.T., Longhurst C.A., Buehler D., Nickel K.P., Iyer G., Kimple R.J, & Baschnagel A.M. (2020). FGFR inhibition enhances sensitivity to radiation in non-small cell lung cancer.. Molecular cancer therapeutics, 19(6), 1255-1265.

+ Open protocol

+ Expand

Xenograft Establishment of Renal Progenitor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Athymic Nude-Foxn1^nu mice from ENVIGO were used in these studies. The mice were housed four to a cage at 22°C under a 12-hour light/dark cycle. Food and water was available ad libitum. Confluent cultures of RPTEC/TERT1, CD133⁺/CD24⁺, and CD133⁻/CD24⁺ cells were trypsinized and cell pellets were re-suspended in ice-cold phosphate buffered saline (PBS) and mixed with an equal volume of ice-cold Corning matrigel (Corning). The cell suspension (0.2 ml) was injected subcutaneously in the dorsal thoracic midline of mice using a 0.2 cc syringe. The matrigel nodules were harvested seven days post injection. The study adhered to all recommendations dictated in the Guide for the Care and Use of Laboratory Animals of the NIH. The specific protocol was approved by the University of North Dakota Animal Care Committee (IACUC#1612–2C).

Shrestha S., Garrett S.H., Sens D.A., Zhou X.D., Guyer R, & Somji S. (2019). Characterization and determination of cadmium resistance of CD133+/CD24+ and CD133−/CD24+ cells isolated from the immortalized human proximal tubule cell line, RPTEC/TERT1. Toxicology and applied pharmacology, 375, 5-16.

+ Open protocol

+ Expand

Flank Xenograft Murine Model for DIPG

Check if the same lab product or an alternative is used in the 5 most similar protocols

Female Hsd:athymic Nude Foxn1nu mice (20 g, Envigo) were kept under specific pathogen-free conditions in air-filtered cages and received food and water ad libitum. The mice were handled in accordance with IACUC guidelines and approval from Mayo Clinic Institutional Committee for Animal Research. The flank xenograft model was established in-house [27 (link)]. Animals were anesthetized with isoflurane and the 5×10⁶ cells/ 200 μL of SU-DIPG XVII cell/Matrigel (1:1, Corning Incorporated, Corning, NY) mixture was implanted subcutaneously into the right flank of the animals. The animals were observed two to three times per week for tumor development, tumor volume (LxWxH) was evaluated twice per week with a digital caliper. When the tumors reached approximately 100 mm³ by caliper measurement, the animals were randomized into vehicle and treatment groups (n = 5–10 per group) and received MNS1-Leu or vehicle once daily for consecutive of 21 days.

Zhang L., Peterson T.E., Lu V.M., Parney I.F, & Daniels D.J. (2019). Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells. PLoS ONE, 14(7), e0220569.

+ Open protocol

+ Expand

Xenograft Tumor Model Establishment

Check if the same lab product or an alternative is used in the 5 most similar protocols

For NCI-H358, NCI-H2122, and LU99 xenograft studies, cells were prepared on the day of implant at a concentration of 3 × 10⁶, 2.5 × 10⁶, 5 × 10⁶ cells, respectively, in a 50:50 ratio of matrigel:cells. A total of 0.1 mL cell suspension/mouse was subcutaneously implanted into the left flank of male athymic nude-Foxn1nu mice (Envigo UK, Strain ID: HSD-069). Once a mean tumor volume of approximately 0.2 cm³ for efficacy studies or 0.5 cm³ for pharmacokinetic-pharmacodynamic studies was reached, mice were randomized into relevant treatment groups. For CT26 (G12C clone P5E6) xenograft studies, 5 × 10⁵ cells were implanted subcutaneously into the right flank of female BALB/cOla mice (Envigo UK, Strain ID: HSD-162). Mice were randomized into relevant treatment groups once a mean tumor volume of approximately 0.2 cm³ was reached.

Chakraborty A., Hanson L., Robinson D., Lewis H., Bickerton S., Davies M., Polanski R., Whiteley R., Koers A., Atkinson J., Baker T., del Barco Barrantes I., Ciotta G., Kettle J.G., Magiera L., Martins C.P., Peter A., Wigmore E., Underwood Z., Cosulich S., Niedbala M, & Ross S. (2022). AZD4625 is a Potent and Selective Inhibitor of KRASG12C. Molecular Cancer Therapeutics, 21(10), 1535-1546.

+ Open protocol

+ Expand

Metastatic Melanoma Inhibition by P2X7 Antagonist

Check if the same lab product or an alternative is used in the 5 most similar protocols

1 × 10⁶ Sk-Mel-28 Luc2 cells were injected into the tail vein of the 6-week-old female athymic nude-Foxn1nu mice (Envigo, Italy). The animals were randomized, and the operator was blinded to the group of allocation. Mice were intra-peritoneum (i.p.) injected with P2X7 antagonist A740003 (50 mg/kg) or vehicle (PBS, 0.005% DMSO) every third day from the inoculum. Cell body dissemination was evaluated thanks to Luc2 luciferase photon emission with an IVIS Lumina Luminometer (Perkin Elmer, USA). Mice were i.p. injected with 150 mg/kg d-luciferin (Promega), and luminescence was captured from ventral view every third day for a total of 33. Photon emission was quantified using the Living Image^® software (Perkin Elmer). 2 × 10⁵ B16-F10 cells were injected into the tail vein of C57bl/6 5–6 weeks old female mice (Envigo). P2X7 antagonist A740003 (50 mg/kg) or vehicle (PBS, 0.005% DMSO) were administered i.p. every third day. On day 18, following sacrifice, mice lungs were explanted, and the number of visible metastasis was evaluated. All animal procedures were approved by the University of Ferrara Ethics committee and the Italian Ministry of Health (Italian D.Lgs 26/204).

Pegoraro A., De Marchi E., Ferracin M., Orioli E., Zanoni M., Bassi C., Tesei A., Capece M., Dika E., Negrini M., Di Virgilio F, & Adinolfi E. (2021). P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death & Disease, 12(12), 1088.

+ Open protocol

+ Expand

Tumor Conditioned Media in Nude Mice

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

This animal study was performed in accordance with the Cornell University animal care guidelines and was approved by Cornell University’s Institutional Animal Care and Use Committee. Three-week-old, female athymic nude-Foxn1^nu mice (n = 5 per condition) were purchased from Envigo and housed five animals per cage with ad libitum access to food and water. For 3 weeks, mice received daily intraperitoneal injections of TCM or blank media control. To generate TCM for injections, MDA-MB-231 breast cancer cells (American Type Culture Collection) at 90% confluency were incubated in serum-free Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% penicillin/streptomycin (Invitrogen) for 24 hours. Conditioned medium was collected, normalized to cell number, concentrated 10-fold in an Amicon centrifugal filter unit (molecular weight cutoff, 3 kDa; EMD Millipore), and subsequently diluted fivefold with serum-free DMEM. Each injection (300 μl in volume) delivered conditioned medium that was produced by an equivalent of 280,000 tumor cells [or a multicellular tumor spheroid with a diameter of ~2 to 3 mm (67 (link))]. Blank low-serum DMEM was processed similarly (control) for mice receiving control injections. TCM and control treatments were prepared in one batch, frozen in aliquots, and thawed immediately before injection to ensure consistency between injections.

Chiou A.E., Liu C., Moreno-Jiménez I., Tang T., Wagermaier W., Dean M.N., Fischbach C, & Fratzl P. (2021). Breast cancer–secreted factors perturb murine bone growth in regions prone to metastasis. Science Advances, 7(12), eabf2283.

+ Open protocol

+ Expand

Neuroblastoma Xenograft in Nude Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Female athymic Nude-Foxn1^nu mice were purchased from Envigo (Bresso, Italy) and housed under pathogen-free conditions. All the experiments were approved by the ethical committee of the Italian Ministry of Health (n: 661/2016-PR) in compliance with the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments). Five-week-old mice were anesthetized with a xylazine–ketamine mix (Xilor 2% plus Imalgene 1000, Merial SpA, Italy), subjected to laparotomy, and inoculated with 1x10⁶ IMR-32 cell line into the left adrenal gland capsule, as previously described [28 (link), 29 (link)].

Corallo D., Pastorino F., Pantile M., Mariotto E., Caicci F., Viola G., Ponzoni M., Tonini G.P, & Aveic S. (2020). Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib. Journal of Experimental & Clinical Cancer Research : CR, 39, 195.

+ Open protocol

+ Expand

Orthotopic Xenograft Tumor Model

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Animal experiments were conducted in accordance with accepted standards of humane animal care and approved by the Animal Care and Use Committee at North Carolina Central University. Xenografts were generated as we previously described [33 (link)]. Briefly, 5-week-old female Hsd:Athymic Nude-Foxn1^nu mice (Envigo, Dublin, VA) were injected orthotopically into the right abdominal mammary gland with 5 × 10⁵ of the indicated cell model suspended in 30.0 μl of 50/50 PBS:Matrigel. Weekly tumor growth was measured via calipers and tumors excised when volume neared 400 mm³. Whole tumors were homogenized and RNA extracted using the Qiagen RNeasy kit as instructed. Three independent experiments were performed to ensure repeatability. Mice that did not form tumors were euthanized 5 months post-injection. Detection of metastatic xenograft cells in liver and lung was conducted as previously described [33 (link)].

Barrow M.A., Martin M.E., Coffey A., Andrews P.L., Jones G.S., Reaves D.K., Parker J.S., Troester M.A, & Fleming J.M. (2019). A functional role for the cancer disparity-linked genes, CRYβB2 and CRYβB2P1, in the promotion of breast cancer. Breast Cancer Research : BCR, 21, 105.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!